Announcements Trials
Browse Landscape

Status

Completed 3

Sponsor Class

INDUSTRY 3

Study Type

Observational 3

Sponsor

Cancer Type

Classical hematology 3

Conditions

Neoplasms 4Venous Thromboembolism 3Treatment of Venous Thromboembolism in Cancer Patients 3Venous Thrombosis 1Thromboembolism 1Pulmonary Embolism 1Pancreatic Neoplasms 1Multiple Myeloma 1Motor Activity 1Liver Neoplasms 1Liver Diseases 1Genital Neoplasms, Female 1Gastrointestinal Neoplasms 1Digestive System Neoplasms 1Digestive System Diseases 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Hepatocellular 1Adenocarcinoma 1

Interventions

Rivaroxaban 3Heparin, Low-Molecular-Weight 3acarboxyprothrombin 1N(4)-oleylcytosine arabinoside 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Completed × Treatment of Venous Thromboembolism in Cancer Patients × Heparin, Low-Molecular-Weight × Clear all
NCT04979780 2024-10-31

OSCAR-US

Bayer

Completed
3,708 enrolled
Classical hematology

Treatment of Venous Thromboembolism in Cancer Patients

NCT05150938 2023-12-18

A Study to Gather Information About Rivaroxaban in Patients in Sweden With Cancer Who Also Have Thrombosis (OSCAR-SE)

Bayer

Completed
5,737 enrolled
Classical hematology

Treatment of Venous Thromboembolism in Cancer Patients

NCT05112666 2023-04-03

A Study to Gather Information About Rivaroxaban in Patients in the United Kingdom Who Have Cancer and Thrombosis (OSCAR-UK)

Bayer

Completed
2,601 enrolled
Classical hematology

Treatment of Venous Thromboembolism in Cancer Patients

Data powered by HemOnc (CC BY 4.0) Colophon âš¡